NCT03892330Not yet recruitingPhase 4
Combination Therapy of Anthracyclines for Children With Nephroblastoma
A Multicenter, Randomized, Double-blind, Prospective Study to Evaluate the Efficacy and Safety of Vincristine, Dactinomycin/Cyclophosphamide Combination Therapy Combined With Liposomal Doxorubicin/Doxorubicin/Pharmorubicin/Pirarubicin in 0.5-14 Year Old Children With Nephroblastoma.
Source: ClinicalTrials.gov · Last updated 27 Mar 2019 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to estimate the efficacy and side effects of study drugs in children with nephroblastoma who are treated with combination therapy.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 25 Mar 2019
- Start date
- 1 Jun 2019
- Primary completion date
- 31 Dec 2020
- Lead sponsor
- Shengjing Hospital
- Diseases
- Kidney cancer, Childhood cancers
- NCT number
- NCT03892330
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 120
- From 1 Jun 2019 to the primary completion date, 31 Dec 2020
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients have been treated with chemotherapy or cardiotoxic nephrotoxic drugs in the past 4 weeks.
- Patients who have undergone mediastinal radiotherapy due to other tumors or received other treatments that may cause heart damage.
Other illness
- Patients with cardiovascular disease in addition to nephroblastoma.
- Patients with digestive, neurological, circulatory, renal or liver disease, blood disorders or growth abnormalities unrelated to the tumor.
- Patients with mediastinal disease.
Other
- Patients have participated in other clinical trials in the past 4 weeks.
Who the study is looking for
- Age 6 months old to 14 years old.
- No smoking history.
- Pathologically confirmed nephroblastoma.
- Informed consent and assent has been obtained before any study assessment is performed.
- Good compliance.
- Need to be applied to anthracycline chemotherapy according to the diagnosis and treatment recommendations for Chinese children with nephroblastoma (current version CCCG-WT-2016).
- Need to be applied to doxorubicin according to the diagnosis and treatment recommendations for children with nephroblastoma (CCCG-WT-2016).
Age in the registry: 6 months to 14 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shenjing Hospital Coordinator of this site? Confirm its status | Shenyang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.